ICV Partners acquires Stauber Performance Ingredients

NewsGuard 100/100 Score

ICV Partners (ICV), a private investment firm focused on investments in smaller middle market companies, announced today the acquisition of Stauber Performance Ingredients, Inc., a value-added distributor of nutraceutical ingredients to the dietary supplement industry, from J. H. Whitney & Co.  Dan Stauber, CEO, and select members of the management team, will continue to have a meaningful ownership interest in the company.

Established over 40 years ago, Stauber Performance Ingredients is a leading distributor of nutraceutical ingredients such as minerals, herbs, fruits, vegetables, nutrients, vitamins and amino acids to the food, pharmaceutical, cosmetic and health food industries. Based in Fullerton, California, Stauber provides value-added services for its customers including procurement, product development and outsourced supply chain management.

Ira Moreland, Managing Director of ICV, said, "We have been evaluating the nutraceutical space for some time and found that Stauber's long history and excellent track record make it a very compelling investment. The company offers a wide breadth of products, the ability to source exclusive ingredients, and is recognized for outstanding customer service.  We believe we can assist in Stauber's future growth by helping to further grow its customer base, expand its product portfolio, and identify new acquisitions that can position it into adjacent markets."

Stauber has relationships with over 100 top manufacturers around the world, including Tomita, Konoshima, FMC, DSM, Brewster, General Chemical, HeSego, VisVitalis and Jungbunzlauer, among other leading companies.

CEO of Stauber Performance Ingredients, Dan Stauber, said, "By focusing on customer satisfaction and innovation, combined with our value-added services such as sourcing, quality control, formulation and turnkey solutions, we have built a strong company with longstanding relationships with our partners. We are now pleased to be working with ICV Partners, and all of our customers and business partners should welcome this new opportunity to expand our capabilities with the management team they know well."

SOURCE ICV Partners

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New sleep-enhancing nutraceutical blend falls short in clinical trial